research use only
Cat.No.S5774
| Related Targets | PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX |
|---|---|
| Other NLRP3 Inhibitors | MCC950 Sodium MCC950 INF39 NLRP3 Inflammasome Inhibitor I Dapansutrile YQ128 NT-0796 BMS-986299 BAL-0028 AZD4144 |
|
In vitro |
DMSO
: 85 mg/mL
(200.74 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 423.43 | Formula | C19H12F3NO3S2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1073612-91-5 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC(=CC(=C1)C(F)(F)F)CN2C(=O)C(=CC3=CC=C(C=C3)C(=O)O)SC2=S | ||
| Targets/IC50/Ki |
NLRP3 inflammasome
|
|---|---|
| In vitro |
CY-09 specifically blocks NLRP3 activation in macrophages. This compound inhibits NLRP3 oligomerization and inflammasome assembly. It directly binds to NLRP3 and inhibits its ATPase activity. The metabolic stability of this chemical was first evaluated using human and mouse liver microsomes, exhibiting favorable stability with the half-life >145 min for both human and mouse microsomes. The metabolic stability of this compound was first evaluated using human and mouse liver microsomes, exhibiting favorable stability with the half-life >145 min for both human and mouse microsomes, which exhibited low risk of drug-drug interactions. |
| In vivo |
CY-09 inhibits NLRP3 activation in vivo and prevents neonatal lethality in a mouse model of CAPS. In pharmacokinetic studies evaluted in C57BL/6J mice administered a single i.v. or oral dose, this compound exhibits favorable pharmacokinetics, with a half-life of 2.4 h, an area under the curve of 8,232 (h·ng)/ml, and bioavailability of 72%. It reverses metabolic disorders in diabetic mice by inhibition of NLRP3-dependent inflammation. This chemical treatment has remarkable beneficial effects for metainflammation, hyperglycemia, and insulin resistance in diabetic mice. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.